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RESULTS:
 
 In all hospitals the drug’s price and the quan-
tity prescribed have an influence on formulary decision-
making, especially for drugs used in the same indication
with similar effectiveness and safety. The drug’s price and
the quantity prescribed seem to have more impact on PH
than on PC. Information about costs avoided by the in-
clusion of a drug in the formulary might have an influ-
ence on decision-making: (1) time spent by nurses (5 PC
and 9 PH); (2) medical devices (2 PC and 5 PH); (3)
shorter hospital stays (2 PC and 4 PH). This information
has little (6 PC and 10 PH) or very little (3 PH) impact
and seems to have even less impact on PH than on PC.
Moreover, published economic evaluations have very lit-
tle impact on decision-making in all hospitals.
CONCLUSION: In hospital formulary development, eco-
nomic information is mostly used for cost-containment
considerations, especially in PH financed on a global
budget basis. The current use of information related to
economic evaluations and to costs avoided by the inclu-
sion of a drug is limited, compared to its potential use.
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The Israeli National Health Law was enacted in January
1995, making health insurance both compulsory and uni-
versal. The law determined a basic list of health services
to which all residents are entitled, and stated that the
government is responsible for funding those health ser-
vices. The National List of Health Services was defined as
the 1994 formulary of Clalit Health Services, Israel’s
largest Sick Fund (3.5 million clients). After the law was
enacted and until December 2000, 152 new drugs were
added to the national formulary and none were removed.
Our hypothesis is that adding new drugs to a formulary
increases the number of prescriptions that patients re-
ceive.
OBJECTIVE: To determine if there was a change in the
average number of prescriptions given to patients of Cla-
lit Health Services in different age groups, between the
years 1996 and 2000.
METHODS: Clalit Health Services’ database was ac-
cessed to determine the number of prescriptions given to
patients in different age groups, who received drug ther-
apy in the years 1996 and 2000.
RESULTS: Children aged 0–18 years received 4.49 annual
prescriptions in 1996 vs. 5.00 in 2000 (D  11%). Patients
between ages 19–45 received 5.93 prescriptions in 1996 vs.
6.34 in 2000 (D  7%). The age group of 46–65 received
14.88 prescriptions in 1996 vs. 16.41 in 2000 (D  10%),
and the elderly age group (66) received 21.63 annual pre-
scriptions in 1996 vs. 33.18 in 2000 (D  53%).
CONCLUSIONS: After adding 152 new drugs to the Na-
tional Drug List, the most significant change in the num-
ber of annual prescriptions was seen in the elderly age
group. These patients are now clearly using more medica-
tions than they used five years ago, although this monthly
average of 2.8 prescriptions per patient is slightly lower
than has been published in other epidemiological studies
from Switzerland and Italy (3.2 to 4.0 on average).
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OBJECTIVES:
 
 The aim of this study is to conduct an en-
vironmental assessment of the Japanese health-care sys-
tem as it enters the year 2002 with a focus on the pros-
pects of the use and impact of pharmacoeconomics. The
drivers, resistors and changes in stakeholder influence on
the pricing and prescribing of pharmaceuticals are exam-
ined as well as Japanese economic evaluations to evaluate
their state of the art and to highlight methodological con-
siderations for future studies.
METHODS: A review of the published and internet liter-
ature in English and Japanese on the Japanese health-care
system was conducted, supplemented by interviews with
representatives from academia, hospitals, pharmacies, the
medical press, industry and government. A systematic review
of Japanese economic evaluations was also conducted us-
ing databases (MEDLINE, OHE-HEED, NHS-EED), and
each study was assessed using a modified 36-point BMJ
quality checklist.
RESULTS: Debate regarding pricing reform has been
taking place since 1997 and submission of economic data
to the MHLW has been optional since 1992 although the
influence of these studies on pricing and reimbursement
is uncertain. Main barriers to economic evaluation are
the lack of Japanese-specific clinical/cost data, low num-
bers of trained pharmacoeconomists, lack of decision-
making expertise/knowledge and organizational disincen-
tives. Thirty-four Japanese economic evaluations were
identified (32 CCA, 1 CEA, 1 CMA), predominantly ad-
dressing screening or diagnostic issues and cancer. 63%
of studies used observational data; 37% contained disag-
gregated presentations, 23% applied discounting, 29%
employed sensitivity analysis and 50% reported ICERs.
CONCLUSIONS: Although Japan is considered a late-
adopter of pharmacoeconomics, there are several encour-
aging signs, e.g., rising numbers of Japanese economic
evaluations and methodological research taking place in
Japan on the Japanese EuroQol, generalizability, impact
and willingness-to-pay. This study offers insights into the
current status of Japanese pharmacoeconomics, particu-
larly barriers that need to be overcome for cost-effective-
ness to be influential on health-care decision-making in
Japan.
